Furthermore, analysis of IL-1B expression in tumour samples from > 1000 patients with stage II/III breast cancer revealed that patients whose primary tumours expressed IL-1B were significantly more likely to develop metastasis to bone (p = 0.017) or other organs (p = 0.0016) compared with patients whose tumours did not express IL-1B, over a 10-year follow-up period [10]. Here, IL1B is linked to breast cancer.